John Charlson, MD
Hematology & Oncology · Milwaukee, WINPI 1386668192
Payments from drug & device makers
Across 240 payments — averaging $6008.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Deciphera Pharmaceuticals Inc.$602K
- Boehringer Ingelheim$289K
- GSK$239K
- Sumitomo Pharma America, Inc.$176K
- Blueprint Medicines Corporation$54K
- Adaptimmune LLC$22K
- plus $60K from 11 others
Across 16 payments — averaging $6225.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ichnos Glenmark Innovation Inc$98K
- GSK$1K
- Eli Lilly$598
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Deciphera Pharmaceuticals Inc. | 105 | $602,248 |
| Boehringer Ingelheim | 38 | $288,723 |
| GSK | 33 | $239,053 |
| Sumitomo Pharma America, Inc. | 6 | $176,185 |
| Blueprint Medicines Corporation | 22 | $53,706 |
| Adaptimmune LLC | 7 | $21,785 |
| Springworks Therapeutics, Inc. | 3 | $16,939 |
| Eli Lilly | 5 | $16,421 |
| Novartis | 4 | $10,160 |
| Novo Nordisk | 1 | $4,625 |
| Ipsen Biopharmaceuticals, Inc | 3 | $4,534 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 4 | $3,446 |
| Aadi Bioscience, Inc. | 4 | $2,265 |
| Boehringer Ingelheim International GmbH | 2 | $1,758 |
| Bristol Myers Squibb | 1 | $125 |
| Syndax Pharmaceuticals, Inc. | 1 | $109 |
| Gilead | 1 | $12 |
How this compares
$1,442,093 in reported general payments places this provider in the 90th percentile of 248 hematology & oncology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Milwaukee
- Binod DhakalMilwaukee$13.9M
- Ehab AtallahMilwaukee$13.3M
- Guru Subramanian Guru MurthyMilwaukee$7.2M
- Parameswaran HariMilwaukee$5.8M
- Meera MohanMilwaukee$5.6M
- Deepak KilariMilwaukee$4.7M
- Kathryn BylowMilwaukee$4.5M
- Sayed Mehdi HamadaniMilwaukee$3.7M
- Anita DsouzaMilwaukee$3.7M
- Sameem AbedinMilwaukee$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.